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 ABSTRACT. The in vitro metabolic behavior was investigated of two chromium tricarbonyl 
derivatives of the antischistosomal drug Praziquantel (PZQ) with the formula (η6-PZQ)Cr(CO)3 
(1 and 2), using human liver microsomes. It could be demonstrated that the metabolic profiles of 
the derivatives differ significantly. The optically pure (η6-PZQ)Cr(CO)3 derivatives, (S, Sp)-1, 
(R, Rp)-1, (S, Rp)-2 and (R, Sp)-2, were also prepared to assess of the eudysmic ratios of 1 and 2 
against S. mansoni. A strong enantioselective antischistosomal activity was observed. The R-
enantiomers are highly active against adult schistosomes in vitro (IC50: 0.08 - 0.13 µM) whereas 
both S-enantiomers lack activity. The in vivo activity of 1 and 2 was then studied in mice 
harboring a chronic Schistosoma mansoni (S. mansoni) infection. A single dose of 1 and 2 (400 
mg/kg) resulted in low worm burden reductions of 24 and 29 % (p>0.05). 
 
 Introduction. 
Schistosomiasis is the second most prevalent parasitic disease in the world after malaria with 207 
million people infected each year. Surprisingly there is only one available drug on the market to 
treat the disease, Praziquantel (PZQ) (Figure 1).1, 2 Despite the identification of various lead 
antischistosomal compounds, no new drugs have entered the market since the development of 
PZQ in 1970s.3 Reliance on a single drug is dangerous and reduced susceptibility of Schistosoma 
mansoni (S. mansoni) to PZQ has already been noted in the field.4-6 The important limitations of 
PZQ make the situation even more precarious. PZQ has low metabolic stability in vivo7, 8 and 
lacks activity against the juvenile stage of Schistosoma.9 Taken together, these facts are a strong 
indication that novel drugs to treat schistosomiasis are required. With this in mind, our groups 
have recently embarked on a project to study the potential of organometallic-containing PZQ 
derivatives as antischistosomal agents. This concept originates from the pioneering work of 
Jaouen, Biot and co-workers on organometallic derivatives of the anticancer agent Tamoxifen 
(Ferrocifens) and the antimalarial Chloroquine (Ferroquine).10, 11 For both Ferrocifens and 
Ferroquine, the addition of a ferrocenyl moiety into the known organic drug allowed the addition 
of novel modes of action to the parent compounds.12, 13 Encouraged by these results, we 
investigated the antischistosomal activity of 18 ferrocenyl derivatives of PZQ.14 Unfortunately, 
only moderate in vitro activity could be determined.14 On the other hand, it was found that two 
(η6-PZQ)Cr(CO)3 derivatives (1 and 2, Figure 1) had in vitro activity against S. mansoni 
comparable to PZQ (nanomolar range).15 These promising in vitro data persuaded us to study in 
more detail the in vivo behavior of 1 and 2. Clearly a promising in vitro activity of a drug 
candidate cannot always be extrapolated into a good in vivo activity since the pharmacokinetics 
and metabolism profile of a drug are key determinants for its in vivo success. It is therefore 
 important to assess the metabolic fate of a drug candidate. As a continuation of our development 
on the (η6-PZQ)Cr(CO)3 derivatives, we present herein the in-depth in vitro metabolic behavior 
of these chromium derivatives as well as their antischistosomal activity in mice infected with 
adult S. mansoni. Importantly, we could demonstrate, by preparing optically active (S, Sp)-1, (R, 
Rp)-1, (S, Rp)-2 and (R, Sp)-2 that, as for the parent drug PZQ, the (η6-PZQ)Cr(CO)3 derivatives 
exhibit enantioselective in vitro antischistosomal activity. 
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Figure 1. Structures of PZQ, (η6-PZQ)Cr(CO)3 derivatives 1 and 2. Note that all the compounds 
presented are racemic mixtures. 
Results and Discussion. 
In Vitro Metabolism Studies. In order to gain insight into the metabolic fate of the racemic (η6-
PZQ)Cr(CO)3 derivatives 1 and 2, we investigated their in vitro metabolic behavior using human 
liver microsomes. Accordingly 1, 2 and PZQ were incubated with human liver microsomes in the 
presence of NADPH at 37 °C (see SI for details). Diazepam which is (known to be stable in 
human liver microsomes) was used as a positive control. After incubation, compounds were 
immediately extracted with dichloromethane which was evaporated to provide residues that were 
analyzed using LC-MS. The metabolites were identified by comparing the differences in the 
respective m/z values in MS spectra with those determined for the parent compound (1 or 2) and 
PZQ (see Table S1, S2 for details). The identities of the major metabolites were further 
 confirmed by comparing the retention time in the UV trace and the mass spectrum from the LC-
MS analysis of authentic samples (vide infra). Semi-quantitative analysis of the ratio of parent 
compound and different metabolites present in the mixture after post incubation with human 
liver microsomes was achieved by comparing the areas under the respective peaks of different 
compounds visible in the UV traces of the LC analysis (see Table S3 for details).  
In the case of 1, formation of two major and three minor metabolites was observed (see Figure 2 
and Table S1 and S3). After 2.5 h a considerable amount (ca. 50 %) of 1 remained unchanged in 
the mixture; the most abundant metabolites, 1.M1 and 1.M2 (22 and 15 %, respectively), were 
detected at retention times of 12.8 and 9.1 minutes, respectively, by LC-MS (positive ion 
electrospray mode). The corresponding MS spectrum for the 1.M1 peak provided base peaks at 
m/z = 313.2 and 335.2 which fit with the species [PZQ+H]+ and [PZQ+Na]+ (MW of PZQ 
312.2), respectively. 1.M1 was therefore identified as PZQ that is formed by loss of the Cr(CO)3 
moiety of 1. This identification was further confirmed by comparing the LC and MS traces of an 
authentic sample of PZQ (Figure S1 in SI). The metabolite 1.M2 was identified as a mono-
hydroxylated species of PZQ (PZQ-OH) from the peaks at m/z = 329.1 and 311.2 in the MS 
spectrum which match with the species [(PZQ-OH)+H]+ and [(PZQ-OH)-H2O+H]+, respectively. 
This metabolite 1.M2 was confirmed to be the cis-4-hydroxypraziquantel (cis-4-PZQ-OH, 
Scheme 1) by comparing the LC-MS traces of the synthetic standards cis-4-PZQ-OH and trans-
4-hydroxypraziquantel (trans-4-PZQ-OH) (Figure S1 in SI).16 The other three minor metabolites 
were detected at retention times of 10.1 (1.M3), 10.5 (1.M4) and 10.9 (1.M5) minutes (Figure 2 
and Table S1). Metabolites 1.M3 and 1.M4 have a similar mass spectrum with an intense peak at 
m/z = 465.1 (Table S1) that matches well the protonated adduct of mono-hydroxylated species of 
1 (Scheme 1). As they are present as trace metabolites in the mixture, further efforts were not 
 made to confirm the structure of these metabolites. The hydroxylation of 1, most likely, occurs in 
the cyclohexane ring or at the tetrahydroisoquinoline part. The minor metabolite 1.M5 also has a 
similar mass spectrum pattern to PZQ-OH with a central peak at m/z = 329.2, which corresponds 
to another mono-hydroxylated derivative of PZQ (see Table S1). Although we could confirm, by 
comparing the UV traces from LC-MS analysis, that 1.M5 is not the trans-4-PZQ-OH (Figure S1 
in SI), we could not structurally characterize 1.M5 due to a lack of any standard matching 
compound. However, as reported earlier, the hydroxylation in 1.M5 is expected to occur either at 
the tetrahydroquinoline part or at the aromatic ring of PZQ.17 A plausible metabolic profile of 1 
explaining the possible routes of formation of metabolites is presented in Scheme 1(a). 
 
Figure 2. UV traces at 220 nm of LC analysis of 1 (left, a and b) and 2 (right, c and d) treated 
with human liver microsomes at t = 0 min and at t = 2.5 h. 
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Scheme 1. Suggested metabolic profiles of 1 (a) and 2 (b) explaining possible routes to form the 
different metabolites. 
Metabolism rate and profile data were obtained for compound 2 that were significantly different 
to those obtained for 1 (Figure 2, right, c) and d) and Table S2). A metabolic profile of 2 is 
schematically presented in Scheme 1. Only a trace amount of 2 was present in the 
microsomes/NADPH mixture after 2.5 h (Table S3). The most abundant metabolite 2.M1 (ca. 
43%) was detected at a retention time of 7.9 minutes. The corresponding ESI-MS peak at m/z = 
339.0 matches well the calculated molecular weight of the protonated species of [(η6-
Praziquanamine)Cr(CO)3 (3), i. e. [3+H]+ (calculated m/z = 339.01). Metabolite 3 can only be 
formed by the cleavage of the amide bond between Praziquanamine and the cyclohexanoyl 
moiety of 2. This type of amide bond cleavage was not observed in the case of 1. The formation 
of 3 was further confirmed by comparing the UV trace of the synthetic standard (See Figure S2 
and Scheme 2 for synthetic details). Formation of six other less abundant metabolites, 2.M2 
(trans-4-PZQ-OH), 1.M2 (cis-4-PZQ-OH), 2.M3 (2-OH), 1.M5 (PZQ-OH) and 1.M1 (PZQ) 
 was also observed and these were characterized from their corresponding UV traces and ESI-MS 
spectra (see Figure S2 and Table S2 in SI). 
The metabolism study of 1 and 2 was authenticated by carrying out a metabolic study on PZQ 
itself using the same assay as for 1 and 2 and by further comparison with previously reported 
results.17-22 As shown in Figure S3 in SI, PZQ was exclusively metabolized to its mono-
hydroxylated species 1.M2 (cis-4-PZQ-OH) and 1.M5 (an unidentified mono-hydroxylated 
derivative). This observation is in good agreement with reports described earlier.17, 22 Formation 
of a trace amount of trans-4-PZQ-OH was also observed. 
Of note, using the experimental conditions and LC-MS setup reported in this study, we did not 
observe the presence of any dehydrogenated metabolites for PZQ, 1 and 2, as previously reported 
for PZQ by Alnouti, Kiec-Kononowicz and co-workers using different analytical techniques 
and/or a slightly different in vitro model (human cytochrome P-450 3A4 expressed in 
Escherichia coli and Saccharomyces cerevisiae instead of microsomes).8, 23 Although we were 
unable to detect any of these metabolites, the possibility of their formation cannot be completely 
ruled out. One can speculate that the dehydrogenated compounds could be formed as minor 
metabolites that co-elute with a major metabolite and that the MS only detects the more abundant 
component present in the mixture.  
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Scheme 2. Synthesis of 3 and optically pure (η6-PZQ)Cr(CO)3 derivatives. Note that 
Praziquanamine, 3 and Iso-3 are racemates. 
In Vitro Antischistosomal Activity Studies of Optically pure (η6-PZQ)Cr(CO)3 derivatives 
and selected metabolites of 1 and 2.  In order to assess if only one enantiomer of compounds 1 
and 2 were active against S. mansoni (as is the case for PZQ) the optically pure (η6-
PZQ)Cr(CO)3 derivatives were prepared using a similar synthetic pathway as for rac-1 and 2 
(see Scheme 2 for details).15 Optically pure PZQ (S-PZQ and R-PZQ),24 was employed as 
starting material (see Figures S4-9 in the SI for chiral HPLC traces). The four new complexes, 
namely (S, Sp)-1, (R, Rp)-1, (S, Rp)-2 and (R, Sp)-2 were tested against adult schistosomes in 
vitro (Table 1). Enantioselective antischistosomal activity was observed for both derivatives. 
Only the (R)-enantiomers exhibited high levels of activity: (R, Rp)-1 with an IC50 value of 0.08 
 µM and (R, Sp)-2 with 0.13 µM. Both (S)-enantiomers lacked activity (IC50 > 66.9 µM). The in 
vitro activity of the major metabolites elucidated for 1 and 2 was likewise tested. As expected, 
high activity was observed for 1.M1 (PZQ) (IC50: 0.1 µM). The second major metabolite of 1 
(1.M2) showed good but 24-fold decreased antischistosomal activity (IC50: 5.9 µM) when 
compared to the parent drug. The major chromium-containing metabolite of 2, 2.M1, presented 
only moderate activity with an IC50 value of 11.6 µM. Taken together, the remarkably 
enantioselective antischistosomal activities observed during the in vitro experiments are a good 
indication that (R, Rp)-1 and (R, Sp)-2 act on the same target(s) as PZQ.8, 25 
Table 1. In vitro activity of compounds 1 and 2, the optically pure enantiomers of 1 and 2 and 
the main metabolites of 1 (1.M1, 1M.2) and 2 (2.M1) against adult S. mansoni. ‘R’ represents 
the “Goodness of fit” which has to be ≥ 0.85) 
 Compound[a] IC50 [µM] R 
Parent 
compounds 
1[b] 0.25 1.0 
2[b] 0.27 1.0 
PZQ 0.10 1.0 
Optically pure 
derivatives 
(R, Rp)-1 0.08 0.9 
(S, Sp)-1 > 66.9  
(R, Sp)-2 0.13 1.0 
 (S, Rp)-2 > 66.9  
Major 
metabolites 
1.M1 (PZQ) 0.1 1.0 
Cis-4-PZQ-OH (1.M2) 5.9 0.9 
3 (2.M1) 11.6 0.9 
[a] Note that 1, 2, PZQ, Cis-4-PZQ-OH (1.M2) and 3 (2.M1) are racemates; [b] data published 
by Patra et al.15  
 
 
In Vivo Antischistosomal Activity Studies. To assess the in vivo potential of the chromium 
tricarbonyl derivatives, 1 and 2 were given orally to mice harboring a chronic S. mansoni 
infection. The racemate mixtures of 1 and 2 were given to mice for comparison purposes with 
 PZQ, which is itself given as a racemate. The results are summarized in Table 2. Treatment of 
mice at a single dose of 400 mg/kg of 1 and 2 resulted in low worm burden reductions of 24 and 
29 % (p>0.05), respectively. In the treatment group of compound 1, two mice died one day post-
treatment whereas one of the mice treated with 2 died 4 days post-treatment. For comparison, at 
this dose (400 mg/kg) worm burden reductions of 96% are achieved with PZQ.26 The toxicity 
observed was unexpected as 1 and 2 did not present any cytotoxicity on the non-cancerous cell 
line MRC-5 up to 100 µM compound concentration.15 The low in vivo activity observed can be 
attributed to the metabolic lability of 1 and 2 resulting in less active metabolites (Table 2). It is 
interesting that both compounds exert a similar low in vivo activity despite compound 1 being 
metabolized to PZQ. However, since S. mansoni live in the mesenteric veins they might not be 
exposed to PZQ before it is metabolised in the liver through first-pass. It can also be 
hypothesized that the relatively low in vivo activity observed is due to protein binding or 
distribution problems. Further experiments outside the scope of this article should be undertaken 
to evaluate these assumptions. 
Table 2. In vivo activity of two racemic (η6-PZQ)Cr(CO)3 derivatives 1 and 2 administered at 
single oral doses of 400 mg/kg to mice harbouring adult S. mansoni. 
Group No. of mice investigated No. of mice cured 
Mean number of 
worms (SD) 
TWR 
[%] 
p-
value 
Control 9 - 36.7 (8.2) - - 
1 5[a] 0 28 (5.9) 24 >0.05
2 5[b] 0 26.3 (19.9) 29 >0.05
PZQ N/A N/A N/A 96[c] N/A 
[a] 2 mice died 24 h post-treatment; [b] 1 mouse died 96 h post-treatment; [c] taken from Dong 
et al.31 N/A: Not available; SD: Standard Deviation; TWR: Total worm burden reduction. 
 
 
 Conclusions 
Taken together, the low in vivo antischistosomal activity as well as toxicity observed for 1 and 2 
compared to PZQ contrast with the remarkable in vitro results previously described15 and further 
emphasize the necessity for in vivo confirmation of in vitro hits. It is important to note that the 
toxicity observed cannot be at least fully attributed to chromium toxicity but might instead have 
been caused by the schistosome infection. The amount of chromium given to the mice (400 
mg/kg of (η6-PZQ)Cr(CO)3 derivatives), assuming a full release of chromium from 1 and 2 as 
well as the oxidation of Cr(0) to the more in vivo stable Cr(III), is insufficient to kill mice: the 
LD50 values of Cr(III) salts are 3.2-15 g/kg, when administered orally in rats.27 Of note, Cr(III) 
has even been used as an antidiabetic agent.28 
In summary in this study we have demonstrated, using human liver microsomes, that two (η6-
PZQ)Cr(CO)3 derivatives, which were previously shown to have in vitro activity against S. 
mansoni comparable to PZQ, were metabolically labile. Clear differences in the rate of 
metabolism and identity of the metabolites produced were observed between 1 and 2. Indeed, 
while 1 was metabolized slowly and produced PZQ and PZQ-OH as the most abundant 
metabolites, 2 was mostly metabolized to 3 and to a lesser extent to PZQ and PZQ-OH. 
Importantly, an enantioselective in vitro antischistosomal activity comparable to PZQ itself was 
determined for the organometallic compounds 1 and 2. These results are a good indication that 
the active form of 1 and 2 bind to the same target(s) as PZQ. Finally, in vivo experiments 
demonstrated that low worm burden reductions of 24 and 29 % (p>0.05) were obtained when a 
single dose of 1 and 2 (400 mg/kg) were given to mice harboring a chronic S. mansoni infection. 
Overall the results presented herein will give valuable information to the rapidly growing field of 
medicinal organometallic chemistry field.29 As highlighted by Hartinger, Metzler-Nolte and 
 Dyson in a recent review about organometallic anticancer compounds, there is an important lack 
of published in vivo studies on non-radioactive bioorganometallic compounds.30 We therefore do 
believe that the work presented in this study will help to fill this important gap and hopefully 
allow more organometallic compounds to become part of drug research and development. 
 
Experimental section. 
Materials. All chemicals were of reagent grade quality or better, obtained from commercial 
suppliers and used without further purification. Solvents were used as received or dried over 
molecular sieves. All preparations were carried out using standard Schlenk techniques. 1, 2, 
praziquanamine, trans-4-PZQ-OH and cis-4-PZQ-OH, R-PZQ and S-PZQ were prepared 
following standard literature procedures.15, 16, 24, 31, 32 The optically pure four (η6-PZQ)Cr(CO)3 
derivatives were prepared using R-PZQ and S-PZQ following a procedure reported for synthesis 
of 1 and 2.15 The purities of compounds (1, 2, (S, Sp)-1, (R, Rp)-1, (S, Rp)-2 and (R, Sp)-2 and 3, 
and cis-4-PZQ-OH) used for biological activity were checked by elemental analysis. The 
enantio-purities of (S, Sp)-1, (R, Rp)-1, (S, Rp)-2 and (R, Sp)-2 were checked using chiral HPLC 
technique and the enantiopurities was found to be ≥ 95%. 
Instrumentation and Methods. 1H and 13C NMR spectra were recorded in deuterated solvents 
on 400 (1H: 400 MHz, 13C: 100.6 MHz) or 500 (1H: 500 MHz, 13C: 126 MHz) MHz 
spectrometers at room temperature. The chemical shifts, δ, are reported in ppm (parts per 
million). The residual solvent peaks have been used as an internal reference. The abbreviations 
for the peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t 
(triplet), q (quartet), m (multiplet), and br (broad). Infrared spectra were recorded on Perkin-
Elmer ATR-FTIR spectrometer. ESI mass spectra were recorded using a Bruker ESQUIRE 6000 
 HCT  quadrupole ion trap instrument (Bruker Daltonik GmbH, Leipzig, Germany), equipped 
with an electrospray ionization source. Waters ACQUITY ultra performance LC (Waters, 
Baden-Dätwill, Switzerland) with a diode array detector was directly interfaced to the ESI ion 
source. LC-MS measurements were run in the following conditions: alternating polarity, 
nebulizer gas (N2) 35 psi, dry gas (N2) 8 l/min, dry temperature 350°C, HV capillary 4000 V, 
HV EndPlate offset –500 V, capillary exit 166 V, skimmer 40 V, trap drive 80, mass range from 
m/z 100 to 2000. For metabolism studies, the Nucleosil 100-5 C18 (250 × 3 mm) reverse phase 
column was used with a flow rate of 0.5 mL min-1 and UV-absorption was measured at 220 nm. 
The runs were performed with a linear gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade) 
and B (distilled water containing 0.02% TFA and 0.05% HCOOH): t = 0-3 min, 20% A; 
t = 7 min, 50% A; t = 16 min, 80% A; t = 19 min, 100% A; t = 22 min, 100% A; t = 25 min, 20% 
A. The level of enantioenrichment of compounds was checked using a Chiralpak® IC 
(250 × 4.6 mm) column fitted to a HPLC apparatus (HITACHI chromaster). The runs were 
performed with a linear gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade) and B (distilled 
water): t = 0-3 min, 70% A; t = 7 min, 90% A; t = 16 min, 90% A; t = 20 min, 100% A; t = 
25 min, 100% A; t = 28 min, 70% A. A flow rate of 1 mL min-1 was used and UV-absorption 
was recorded at 250 nm. 
Determination of in vivo activity against Schistosoma mansoni. Studies were approved by the 
local veterinary agency (permission no. 2070). Female NMRI mice (n=19, obtained from Harlan 
Laboratories (Horst, the Netherlands)), were subcutaneously infected with ~ 100 cercarciae 
following standard procedures.33 Groups of 5 infected NMRI mice characterized by a patent S. 
mansoni infection (49 days post-infection) were treated orally with the test drugs using single 
oral doses (400 mg/kg). Untreated mice (n=9) served as controls. Fourteen days post-treatment 
 animals were sacrificed by the CO2 method and dissected. Worms were sexed and counted.34 
Worm burdens of treated mice were compared to control animals and reductions of worm burden 
calculated. To compare the medians of the responses between the treatment and control groups 
the Kruskal-Wallis test was utilized. A difference in median was considered to be significant at a 
significance level of 5%. 
Determination of in vitro activity against Schistosoma mansoni.  
Schistosomes were cultured in RPMI 1640 culture medium (supplemented with 5% inactivated 
fetal calf serum (iFCS) and 100 U/mL penicillin as well as 100 µg/mL streptomycin (Invitrogen, 
Carlsbad, USA)) at 37 °C in an atmosphere of 5% CO2. All compounds of interest were tested at 
a concentration range of 0.11 - 30 µg/ml (0.11, 0.33, 1.1, 3.3, 10 and 30 µg/ml), using DMSO 
stock solutions (conc. 10 mg/ml; final concentration of DMSO: 0.3 %) diluted in supplemented 
RPMI 1640 medium within 24 flat bottom well plates (BD Falcon, USA) with a final volume of 
2 ml per well.35 Three worms of both sexes, were placed into each well. Wells with the highest 
concentration of DMSO in medium served as controls. Praziquantel served as positive control. 
Phenotypes were monitored after 72 h using the motility scale described by Ramirez et al.36 and 
an inverse microscope (Carl Zeiss, Germany, magnification 80x). Each experiment was 
performed three times. IC50 values of active compounds and positive control were calculated 
using CompuSyn software (Version 3.0.1, 2007; ComboSyn, Inc) as described before.35 
Metabolic stability studies. Human microsomes (Gibco) at a concentration of 20 mg/ml were 
slowly thawed on ice. 10 µl microsomes (0.46 mg/ml final concentration) were then incubated in 
a water bath with 382 µl of 100 mM phosphate buffer (pH 7.4), 4 µl of a 20 mM NADPH 
solution, 2.5 µl of the tested compound (stock solution: 5 mM in DMSO, final concentration 0.03 
mM) and 2.5 µl of Diazepam (stock solution: 1 mM in DMSO:, final concentration 0.006 mM) 
 for 5 min at 37C. Following this, the reaction was initiated by adding another 30 µl of a 20 mM 
NADPH solution (1.6 mM final concentration), the mixture was then incubated for required time 
at 37C while shaking slowly (final DMSO concentration: 1.16 %). The reaction was then 
stopped by addition of 2 ml CH2Cl2. Sample was vortex and centrifuged for 5 min at 1000xg. 
The CH2Cl2 layer was taken up carefully and evaporated using a N2-flow. The residue was 
dissolved in 100 µl of 8:5 ACN:H2O (containing 0.02% TFA + 0.05% HCOOH) and 40 µl was 
injected in LC-MS. 
 (η6-Praziquanamine)Cr(CO)3 (3). A solution of praziquanamine (298 mg, 1.48 mmol) in 30 mL 
of Bu2O/THF (8:1) was degassed by two freeze-thaw cycles. Cr(CO)6 (488 mg, 2.2 mmol) was 
added to the solution and was degassed again by one more freeze-thaw cycle. The reaction 
mixture was heated at 140°C under a nitrogen atmosphere in dark for 30 h. The resulting yellow 
solution was then cooled to room temperature and solvent was removed, the residue was re-
dissolved in CH2Cl2 and filtered through a celite pad and concentrated. The residue was 
subjected to silica column chromatography for two times (eluent: EtOAc:MeOH:NEt3 20:1:0 → 
10:1:0.1→ 10:2:0.3) to remove the impurities and  minor isomer Iso-3. Compound 3 was obtain 
as yellow solid (70 mg, 14%). Retention time = 7.9 min (RP-HPLC). 1H NMR (500 MHz, 
CDCl3): δ (ppm) 2.61-2.65 (m, 1H), 2.82-3.01 (m, 3H), 3.61-3.69 (m, 3H), 4.61-4.79 (m, 2H), 
5.15-5.27 (m, 2H), 5.39 (m, 1H), 5.51 (m, 1H). 13C NMR (126 MHz, CDCl3): δ (ppm) 27.1, 
38.9, 50.1, 50.4, 53.2, 88.2, 89.9, 90.1, 92.4, 108.1, 109.7, 157.1, 232.1. ESI-MS (pos. detection 
mode): m/z (%): 339.1 (100) [M+H]+. IR bands(ν): 1940 and 1855 (Cr-CO) cm−1. Anal. calcd. 
for C15H14CrN2O4·MeOH: C 52.54, H 4.55, N 7.91. Found: C 52.37, H 4.59, N 7.84. 
 
ASSOCIATED CONTENT 
 Supporting Information. UV traces at 220 nm of the LC-MS analysis of 1, 2 and PZQ after 
incubated with human liver microsome (Figures S1-S3). Tables showing the detection of the 
metabolites of 1 and 2 by LC-MS (Table S1-S2). Chiral HPLC traces of optically pure PZQ and 
(η6-PZQ)Cr(CO)3 (Figures S4-S9). This material is available free of charge via the Internet at 
http://pubs.acs.org 
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